… for rare genetic diseases. Our most advanced development programs are focused on a group of rare diseases affecting … Besides the technologies underlying our development programs, we invented the Axiomer technology that enables … and the groundbreaking science underlying our pipeline programs were published by world-class key opinion leaders as …
… for RNA therapies. One major issue with RNA therapies in general is that it’s difficult to deliver it intact to the … a year, for the foreseeable future. Once we get the first programs I just described done, and we’ve established the … will be able to help a lot more patients.” Ophthalmology Programs Source: ProQR’s Annual Magazine 2018 Learn more …
… injection in the back of the eye, without any general anesthesia. But with gene therapy, you have to do … at the back of the eye. This does require the use of general anesthesia, and it actually only targets the central …
… to make great progress with our clinical development programs. Our first molecule, QR-010 for cystic fibrosis is … increased investments in our other pipeline programs. General and administrative costs increased to €2.6 million …
… all patients expected in 2019 Presented two abstracts on programs for Fuchs endothelial corneal dystrophy and … development of QR-421a and other pipeline programs. General and administrative costs increased to €2.7 million …
… development effort to rapidly advance the pipeline programs into the clinic. ProQR was granted two key patents, … license to US patent no. 9,617,535 from Massachusetts General Hospital covering QR-010. During the 2017 Annual …
